Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBECO SSI for Moderate to Severe Crohn's Disease
NCT03472690Phase 2Terminated
- Sponsor
- Qu Biologics
- Start
- Jun 2018
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of QBECO SSI in Crohn's disease, sponsored by Qu Biologics. Started Jun 2018; status: terminated.
02
Drugs
QBECO SSI
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03472690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472690.